Dose escalation in intrathecal baclofen therapy based on disease etiology: Can an a priori target dose be established? A ten-year follow-up study,The Journal of Spinal Cord Medicine

当前位置： X-MOL 学术 › J. Spinal Cord Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dose escalation in intrathecal baclofen therapy based on disease etiology: Can an a priori target dose be established? A ten-year follow-up study
The Journal of Spinal Cord Medicine ( IF 1.7 ) Pub Date : 2023-11-20 , DOI: 10.1080/10790268.2023.2266614
Muhammet Enes Gündüz ₁ , Finn Haak ₁ , Veerle Visser-Vandewalle ₁ , Georgios Matis ₁

Affiliation

Intrathecal baclofen (ITB) therapy is administered for severe, persistent spasticity that cannot be addressed by oral medication or other treatments.We aimed to evaluate the target dose of ITB for ...

中文翻译：